The results of total adverse events showed that compared with control group, Azvudine group had lower incidences of hypophosphatemia (p = 0.005), had higher incidences of lymphocyte count decreased (p < 0.001), lymphocyte count increased (p = 0.013), anemia (p = 0.009), hypokalemia (p < 0.001), ALT increased (p = 0.006), and hypertriglyceridemia (p = 0.011). The gene discussed is GPT; the disease is hypophosphatemia.